Revolution Medicines’ drug, known as Rasonque or daraxonrasib, nearly doubled patients’ average survival times in treating one of the deadliest cancers, the agency said. The Food and Drug Administration had expanded access for daraxonrasib in May as it underwent review, stating that the drug met a critical need in treating pancreatic cancer. |
No comments:
Post a Comment